US Edition
Microphysiological systems for mAbs development
Summary by CN Bio Innovations
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Microphysiological systems for mAbs development
Welcome to part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs). In part one of the blog, we unpicked the reasons behind the FDA’s decision to focus on mAbs first, and steps to ensure that a NAM-based approach will offer the same degree of safety as animals before their use is phased …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
